南非HIV感染儿童在WHO推荐ART方案下的耐药突变
该队列研究纳入2012至2014年南非5家公立机构72例接受WHO推荐一线ART的HIV感染儿童,随访24个月。最终检测显示80.6%存在至少一个耐药突变,NNRTI和NRTI耐药突变分别占65%和51%;ABC/3TC/EFV组残留有效药物不足者比例高于ABC/3TC/LPV/r组。
要点
- 接受WHO推荐一线ART的HIV感染儿童中耐药突变率高达80.6%。
- NNRTI和NRTI耐药突变分别占65%和51%,与ART方案无统计学差异。
- ABC/3TC/EFV组47.8%仅剩0或1种有效药物,高于LPV/r组的8.2%。
核心结论
- 接受ABC/3TC/LPV/r的儿童中NNRTI和NRTI耐药突变高发,提示失败的母亲至儿童传播干预对耐药突变有持久影响。
- ABC/3TC/LPV/r组可检测到病毒血症的儿童比ABC/3TC/EFV组更可能维持至少2种有效药物。
研究设计与样本
- 前瞻性队列研究,纳入2012至2014年南非5家公立机构的0-12岁ART初治HIV感染儿童,随访至24个月。
- 最终研究访视时采集干血斑样本进行病毒载量和基因型耐药检测,72例成功获得基因型。
主要发现
- 72例成功基因型儿童中,49例(68.1%)接受ABC/3TC/LPV/r,23例(31.9%)接受ABC/3TC/EFV。
- 80.6%(58/72)存在至少一个耐药突变;NNRTI耐药突变占65%,NRTI耐药突变占51%,按ART方案无统计学差异。
- ABC/3TC/EFV组47.8%(11/23)当前方案中仅剩0或1种有效抗逆转录病毒药物,ABC/3TC/LPV/r组为8.2%(4/49)。
临床怎么用
- 对接受WHO推荐一线ART的HIV感染儿童应关注耐药突变风险,尤其是NNRTI和NRTI类。
- 病毒学失败时,ABC/3TC/EFV方案比ABC/3TC/LPV/r方案更易出现有效药物不足,需优先评估耐药并调整方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children living with human immunodeficiency virus (HIV) (CLHIV) receiving antiretroviral therapy (ART) in resource-limited settings are susceptible to high rates of acquired HIV drug resistance (HIVDR), but few studies include children initiating age-appropriate World Health Organization (WHO)-recommended first-line regimens. We report data from a cohort of ART-naive South African children who initiated first-line ART. METHODS: ART-eligible CLHIV aged 0-12 years were enrolled from 2012 to 2014 at 5 public South African facilities and were followed for up to 24 months. Enrolled CLHIV received standard-of-care WHO-recommended first-line ART. At the final study visit, a dried blood spot sample was obtained for viral load and genotypic resistance testing. RESULTS: Among 72 successfully genotyped CLHIV, 49 (68.1%) received ABC/3TC/LPV/r, and 23 (31.9%) received ABC/3TC/EFV. All but 2 children on ABC/3TC/LPV/r were <3 years, and all CLHIV on ABC/3TC/EFV were ≥3 years. Overall, 80.6% (58/72) had at least one drug resistance mutation (DRM). DRMs to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) were found among 65% and 51% of all CLHIV, respectively, with no statistical difference by ART regimen. More CLHIV on ABC/3TC/EFV, 47.8% (11/23), were found to have 0 or only 1 effective antiretroviral drug remaining in their current regimen compared to 8.2% (4/49) on ABC/3TC/LPV/r. CONCLUSIONS: High levels of NNRTI and NRTI DRMs among CLHIV receiving ABC/3TC/LPV/r suggests a lasting impact of failed mother-to-child transmission interventions on DRMs. However, drug susceptibility analysis reveals that CLHIV with detectable viremia on ABC/3TC/LPV/r are more likely to have maintained at least 2 effective agents on their current HIV regimen than those on ABC/3TC/EFV.
引用
- Hackett S, Teasdale CA, Pals S, et al. Drug Resistance Mutations Among South African Children Living With HIV on WHO-recommended ART Regimens. Clin Infect Dis. 2021. PMID: 32735012. doi:10.1093/cid/ciaa1068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。